Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
The company allocated €56 million to research and development for next-generation line solutions
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
